Virbac Shares Decline at Close Despite Upward Revisions

Renewed Interest from Analysts

The Virbac case has seen renewed interest from research offices. On January 22, BNP Paribas Exane raised its price target from 400 to 440 euros, while maintaining its 'outperform' recommendation. This target implies a potential appreciation of 20.5% compared to the closing price. The day before, IDMidcaps also adjusted its valuation, raising its target from 410 to 420 euros with a buy recommendation. These successive revisions reflect the analysts' confidence in the prospects of the veterinary pharmaceutical laboratory, even though the market has not yet fully integrated these positive expectations.

Favorable Technical Outlook

From a technical perspective, Virbac maintains a favorable configuration. The stock is trading above its 20-day moving average, positioned at 360.10 euros, indicating a constructive short-term trend despite the slight session decline. This configuration demonstrates the relative strength of the stock's market performance. The 14-day RSI stands at 57, a level in the neutral zone that signals neither overheating nor overselling. This indicator allows room for potential progress without entering an overbought zone. Over a week, the variation remains limited to -0.55%, while the past quarter shows a modest increase of 0.83%, confirming a consolidation phase after a notable appreciation of nearly 16% in 2025.